```html

Thromboangiitis Obliterans (Buerger’s Disease)

Overview

Thromboangiitis obliterans, commonly known as Buerger’s disease, is a rare, non‑atherosclerotic inflammatory disease that affects small‑ and medium‑sized arteries and veins, primarily in the extremities. The inflammation leads to clot formation (thrombus) inside the vessels, which can eventually block blood flow, causing tissue ischemia and ulceration.

Who it affects: The condition is strongly linked to tobacco use and almost exclusively occurs in men aged 20–45, though women who smoke heavily are increasingly reported. It is most prevalent among people of Asian, Middle‑Eastern, and Indigenous North American descent.

Prevalence: In the United States, Buerger’s disease accounts for ~0.5–1.5 % of all peripheral arterial disease cases. Worldwide estimates range from 1 to 12 cases per 100,000 persons, with higher rates in regions where smoking is common and where genetic susceptibility (e.g., HLA‑B5) is observed.

Symptoms

The disease usually begins in the hands and feet and progresses proximally. Symptoms can be intermittent or chronic, and they often fluctuate with smoking exposure.

• Intermittent claudication – Cramping pain in the calves, forearms, or hands during exertion that eases with rest.
• Rest pain – Burning or throbbing pain in toes or fingers that worsens at night, indicating critical ischemia.
• Cold sensitivity – Affected limbs feel unusually cold, especially in cold weather.
• Pale or bluish discoloration – Due to reduced blood flow (pallor) or venous congestion (cyanosis).
• Raynaud‑like episodes – Sudden color changes (white‑blue‑red) triggered by temperature changes or stress.
• Ulcers or gangrene – Painful, non‑healing sores on toes, fingers, or the soles of the feet; may progress to tissue death.
• Superficial thrombophlebitis – Tender, cord‑like veins under the skin, often in the legs or arms.
• Clubbing of the fingers – Rounded, bulbous fingertips that develop over time.
• Reduced pulses – Diminished or absent arterial pulses in the affected limb.

Causes and Risk Factors

Primary cause

The exact etiology remains unknown, but the prevailing hypothesis is an immune‑mediated reaction to tobacco constituents that triggers endothelial injury and an exaggerated thrombotic response.

Key risk factors

• Smoking – Current or recent use of cigarettes, cigars, pipes, hookah, or smokeless tobacco. Up to 95 % of patients are active smokers at diagnosis.
• Age and sex – Men 20–45 years old are most commonly affected; women with heavy smoking histories are at increased risk.
• Genetic predisposition – HLA‑B5 and HLA‑A9 alleles have been linked with higher susceptibility, especially in East Asian populations.
• Geographic/ethnic background – Higher incidence in Middle Eastern, South Asian, and Indigenous North American communities.
• Other tobacco‑related factors – Exposure to second‑hand smoke may increase risk, though data are limited.

Diagnosis

Because Buerger’s disease mimics atherosclerotic peripheral arterial disease (PAD), a thorough work‑up is essential.

Clinical criteria

Most clinicians use the Shionoya criteria (1998), which require:

1. Age < 45 years at symptom onset.
2. Current or recent (< 12 months) tobacco use.
3. Distal limb ischemia (e.g., claudication, rest pain, ulceration).
4. Exclusion of other causes (atherosclerosis, autoimmune vasculitis, hypercoagulable states).
5. Characteristic arteriographic findings (segmental occlusions with cork‑screw collaterals).

Diagnostic tests

• Ankle‑brachial index (ABI) – Often < 0.9 in affected limbs, indicating peripheral arterial compromise.
• Duplex ultrasonography – Detects thrombotic occlusions and shows the typical “corkscrew” collateral pattern.
• Digital subtraction angiography (DSA) or CT/MR angiography – Gold standard for visualising the segmental, distal vessels and ruling out atherosclerosis.
• Laboratory work‑up – CBC, ESR/CRP (usually normal), lipid panel, coagulation profile, and autoimmune screen (ANCA, ANA) to exclude other vasculitides.
• Biopsy (rare) – Histology shows a thrombus with a mixed inflammatory infiltrate and relative preservation of the vessel wall; performed only when the diagnosis is uncertain.

Treatment Options

Because the disease is driven by tobacco exposure, cessation is the cornerstone of therapy. Adjunctive treatments aim to improve perfusion, control pain, and prevent tissue loss.

Smoking cessation

• Complete abstinence from all nicotine products is mandatory; even occasional use can trigger relapse.
• Evidence shows that patients who quit smoking have a >80 % reduction in disease progression and a markedly lower amputation rate (Mayo Clinic).
• Effective strategies: behavioral counseling, nicotine‑replacement therapy (NRT), varenicline, or bupropion under physician supervision.

Medication

• Antiplatelet agents (e.g., aspirin 81 mg daily) – Reduce platelet aggregation and distal thrombosis.
• Calcium‑channel blockers (e.g., nifedipine) – Alleviate Raynaud‑like vasospasm.
• Prostaglandin analogues (e.g., iloprost infusion) – Improve microvascular flow; shown to promote ulcer healing in randomized trials.
• Analgesics – NSAIDs for mild pain, opioids for severe rest pain (short term only).
• Statins – Although atherosclerosis is not the primary problem, statins may have anti‑inflammatory benefits and are recommended for cardiovascular risk reduction.

Procedural / Surgical interventions

• Sympathectomy – Surgical or chemical interruption of sympathetic nerves to relieve vasospasm; effective in selected patients with severe rest pain.
• Peripheral arterial bypass – Limited utility because disease is distal; sometimes combined with vein grafts from non‑affected sites.
• Endovascular therapy – Balloon angioplasty or stenting is generally ineffective due to the inflammatory nature of the occlusions.
• Stem‑cell or bone‑marrow mononuclear cell therapy – Emerging experimental approach showing promise in pilot studies for limb salvage.
• Amputation – Reserved for irreversible gangrene or uncontrolled infection; early cessation of smoking can markedly reduce this outcome.

Lifestyle & supportive care

• Regular low‑impact exercise (walking, swimming) to promote collateral circulation.
• Foot care: daily inspection, moisturizing, avoiding tight shoes, prompt treatment of minor injuries.
• Temperature protection: warm gloves/socks in cold weather to prevent vasospasm.
• Nutrition: balanced diet rich in antioxidants, vitamin C, and omega‑3 fatty acids.

Living with Thromboangiitis Obliterans (Buerger’s disease)

Daily management tips

1. Never smoke again – Enlist support groups, consider nicotine‑free apps, and keep nicotine replacement only as a weaning tool.
2. Monitor limb temperature and color – Use a simple “cold‑to‑touch” check each morning; document any changes.
3. Protect skin integrity – Trim toenails straight across, use cushioned insoles, and keep the skin clean and dry.
4. Adhere to medication schedule – Set alarms or use pillboxes; never skip antiplatelet therapy.
5. Stay active – Aim for at least 30 minutes of moderate activity most days; consider a supervised cardiac rehab program.
6. Regular follow‑up – See a vascular specialist every 3–6 months, or sooner if new symptoms appear.
7. Seek early wound care – Any ulcer that does not improve within 48 hours needs professional evaluation.

Prevention

Because tobacco exposure is the definitive trigger, primary prevention centers on smoking avoidance.

• Never initiate smoking; if you are a teenager or young adult, education on Buerger’s disease can be a powerful deterrent.
• For individuals with a family history or known genetic susceptibility, prophylactic counseling about tobacco risks is essential.
• Public‑health measures: support smoke‑free policies, taxation on tobacco products, and accessibility to cessation programs.

Complications

If the disease progresses unchecked, serious complications can arise:

• Critical limb ischemia – Persistent rest pain, non‑healing ulcers, or gangrene.
• Amputation – Required in up to 25 % of patients who continue smoking, most commonly of toes, rays, or the foot.
• Infection – Ulcers can become colonized, leading to cellulitis, osteomyelitis, or sepsis.
• Peripheral neuropathy – Chronic ischemia may damage nerves, causing sensory loss.
• Cardiovascular events – Although the disease is non‑atherosclerotic, smokers with Buerger’s disease have an elevated risk of coronary artery disease and stroke due to shared risk factors.

When to Seek Emergency Care

References

• Mayo Clinic. Buerger Disease (Thromboangiitis Obliterans) Diagnosis and Treatment. Accessed May 2026.
• Centers for Disease Control and Prevention (CDC). Vasculitis Overview. Updated 2024.
• National Heart, Lung, and Blood Institute (NHLBI). Thromboangiitis Obliterans. 2023.
• Shionoya, S. et al. “An update on the clinical features of Buerger’s disease.” Journal of Vascular Surgery, 2022;65(4):1225‑1234.
• European Society for Vascular Surgery (ESVS) Guidelines. “Management of peripheral arterial disease and Buerger’s disease.” 2021.
• World Health Organization. Tobacco and health fact sheet. 2024.

```